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Abstract
Background: The clinical benefits associated with targeted oncology agents are generally limited to subsets of
patients. Even with favorable biomarker profiles, many patients do not respond or acquire resistance. Existing
technologies are ineffective for treatment monitoring as they provide only static and limited information and
require substantial amounts of tissue. Therefore, there is an urgent need to develop methods that can profile
potential therapeutic targets with limited clinical specimens during the course of treatment.
Methods: We have developed a novel proteomics-based assay, Collaborative Enzyme Enhanced Reactive-
immunoassay (CEER) that can be used for analyzing clinical samples. CEER utilizes the formation of unique
immuno-complex between capture-antibodies and two additional detector-Abs on a microarray surface. One of
the detector-Abs is conjugated to glucose oxidase (GO), and the other is conjugated to Horse Radish Peroxidase
(HRP). Target detection requires the presence of both detector-Abs because the enzyme channeling event
between GO and HRP will not occur unless both Abs are in close proximity.
Results: CEER was able to detect single-cell level expression and phosphorylation of human epidermal growth
factor receptor 2 (HER2) and human epidermal growth factor receptor 1 (HER1) in breast cancer (BCa) systems. The
shift in phosphorylation profiles of receptor tyrosine kinases (RTKs) and other signal transduction proteins upon
differential ligand stimulation further demonstrated extreme assay specificity in a multiplexed array format. HER2
analysis by CEER in 227 BCa tissues showed superior accuracy when compared to the outcome from
immunohistochemistry (IHC) (83% vs. 96%). A significant incidence of HER2 status alteration with recurrent disease
was observed via circulating tumor cell (CTC) analysis, suggesting an evolving and dynamic disease progression.
HER2-positive CTCs were found in 41% (7/17) while CTCs with significant HER2-activation without apparent over-
expression were found in 18% (3/17) of relapsed BCa patients with HER2-negative primary tumors. The apparent
‘HER2 status conversion’ observed in recurrent BCa may have significant implications on understanding breast
cancer metastasis and associated therapeutic development.
Conclusion: CEER can be multiplexed to analyze pathway proteins in a comprehensive manner with extreme
specificity and sensitivity. This format is ideal for analyzing clinical samples with limited availability.
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Breast cancer is a collection of diseases with distinct his-
topathological features and diverse prognostic outcomes.
As the field rapidly progresses towards understanding
the diverse biology of breast cancers, we are presented
with a range of treatment options to treat this malig-
nancy. Owing to the differences in response to treat-
ment, the search for a tool to differentiate breast cancer
subtypes and to predict response when patients are
newly diagnosed or when the disease has recurred has
been intense.
A classic example is the HER2-positive breast cancers
that comprise approximately 25-30% of breast cancers
[1,2]. HER2 is a receptor member of the ErbB receptor
tyrosine kinase (RTK) family that is activated by phos-
phorylation after dimerization with other receptor mem-
ber partners to initiate pathway signaling. Over-
expression of HER2 triggers cell proliferation and dis-
e a s ep r o g r e s s i o n ,a n dH E R 2 - p o s i t i v eB C ah a v eah i g h e r
recurrence rate and reduced survival [1]. With the
advent of HER2-targeted therapies, most notably trastu-
zumab, the natural progression of HER2-positive breast
cancers can be dramatically blunted [3,4]. Therefore,
HER2 overexpression is accepted as a strong predictive
marker for clinical benefits from trastuzumab [5]. How-
ever, only approximately 50% of HER2-positive patients
initially respond to trastuzumab-complemented treat-
ments while the rest show inherent resistance and can
metastasize to distant sites. Even the patients who
demonstrate a dramatic initial response to trastuzumab
eventually develop resistance [6]. If there were a way to
prospectively predict the course of breast cancer pro-
gression and strategically segregate the responders from
the non-responders, it would eliminate uncertainty in
treatment and save valuable time providing most effec-
tive evidence-based therapeutic outcome.
Multi-target assessments of gene expression in normal
and abnormal tissues have expanded our understanding
of the pathophysiology of many diseases including breast
cancers. While mRNA profiling can provide valuable
biological information, its clinical potential may be lim-
ited because the mRNA levels may or may not corre-
spond to the expressed protein levels. Despite these
limitations, advances made in basic and translational
research have resulted in the incorporation of genomic
technologies into clinical use for complex diseases such
as cancer, thus paving the way for new genomic-based
patient management [7,8]. Multiplexed genomic-analysis
matured due to the exquisite sensitivity and specificity
of molecular technologies based on sequence-specific
target amplification processes.
In contrast, proteomic-based methods have not yet
developed into a practical multiplexed format. Most cur-
rent protein-based applications are based on traditional
IHC principles, which are semi-quantitative at best and
require a substantial amount of sample. The more suc-
cessful clinical application of proteomics technologies
awaits better sensitivity and specificity. Additionally, an
efficient proteomics-based diagnostic platform must be
able to differentiate the level of total protein expression
from the degree of protein activation as the activated
state of the proteins reflects their impact on cellular
functions.
One of the most widely used current clinical applica-
tions of proteomic assessments for therapeutic/prognos-
tic outcome is with the detection of HER2 protein
expression in BCa patients using IHC. However, this
method has technical limitations with analytical sensitiv-
ity, target specificity, capacity to multiplex, and subjec-
tivity in image interpretation [9,10]. Furthermore,
significant discordance between the results of HER2 stu-
dies performed in different laboratories has been
reported [11]. Hence fluorescence in situ hybridization
(FISH) technology is currently used to detect HER2
gene amplification when the IHC-based results are
ambiguous. A staged use of both technologies is used to
determine patient eligibility for trastuzumab [12].
Although HER2-IHC and HER2-FISH are valuable for
preliminary patient selection, neither test can accurately
differentiate trastuzumab responders from non-respon-
ders. A further limitation of both these assay methods is
their inability to determine the activation status of the
HER2 protein. Therefore, there is a definite need for a
proteomics-based method to identify unequivocally
which HER2-positive breast cancer patients will respond
to HER2-targeting agents. Such methods should be able
to determine the functional state of HER2 along with
the profile of its potential dimerization partners, in
order to provide vital information for rational selection
of the most effective therapy option. Another valuable
characteristic of a versatile diagnostic test would be if it
could molecularly evaluate breast cancer progression
with high sensitivity and specificity on limited amounts
of clinical material. As tumors are extremely heteroge-
neous, the tumor cells at the primary site of occurrence
may not necessarily reflect the profile of the tumor cells
in recurrent disease. A relevant source of tumor cells
for capturing metastases of recurrent disease may be the
CTCs found in peripheral blood [13-16]. Although sam-
ple volume may be limited, these provide valuable
opportunities to perform a non-invasive “real-time liquid
biopsy” on metastatic cancer patients.
We have developed a novel microarray-based proteo-
mic platform, Collaborative Enzyme Enhanced Reactive-
immunoassay (CEER; Figure 1) that has ultra-high sensi-
tivity and specificity due to its unique configuration. It
can simultaneously detect the activation state of multi-
ple signal transduction proteins at the single cell level
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(or between 1 × 10
4 to 1 × 10
5 target molecules). Here
we report the successful application of CEER to quanti-
tate the total expression and the activation state of a
number of RTKs including HER2 and other downstream
signaling pathway proteins in several breast cancer cell
lines, xenografts, and breast cancer clinical samples. We
further present evidence that CEER can be successfully
used to analyze CTCs from metastatic breast cancer
patients that can aid treatment decisions for HER2-tar-
geting agents. We demonstrate that novel biological
aspects of breast cancer progression can be uncovered
by directly analyzing clinical samples using the CEER
technology.
Results
CEER can detect ErbB-RTK activation status at the single
cell level in breast cancer cell lines
CEER was used to detect the expression and activation
(phosphorylation) of HER1 and HER2, receptor mem-
bers of the ErbB-RTK family, at a sensitivity level of a
single cell in breast cancer cell lines, MDA-MB-468 and
SKBr3, respectively (Figure 2a). These cell lines have
been well characterized for their ErbB-RTK expression
status [17-21]. Although RTK expression is approxi-
mately 1 to 2 × 10
6 HER1 or HER2 receptors per cell in
MDA-MB-468 and SKBr3, respectively, only subsets of
these receptors are phosphorylated at any given
instance. However, the small percentage of phosphory-
lated receptors in these cell lines is sufficient to drive
downstream pathway activation and breast cancer cell
proliferation [18]. Therefore, to efficiently detect HER1
and HER2 receptor activation at a single cell level in
breast cancer cells, it is necessary to detect these subsets
of phosphorylated receptors.
While HER2 over-expressing SKBr3 cells demonstrate
constitutive HER2 activation, MDA-MB-468 cells need to
be stimulated with HER1-specific EGF ligand to induce
HER1 phosphorylation [17,18]. As expected and as shown
in Figure 2b, differential activation of HER1 and HER2
occurs in cell lines expressing varying levels of ErbB recep-
tor family members and when they are stimulated by
either EGF (for direct HER1 stimulation via homo or het-
erodimerization) or HRG (for indirect stimulation of
HER2 via heterodimerization with HER3). While MDA-
MB-468 cells did not show any HER1 activation at basal
Figure 1 Configuration of Collaborative Enzyme Enhanced Reactive-immunoassay (CEER). When target proteins are bound to specific
capture antibodies printed on nitrocellulose surface after incubating with cell lysate, unbound non-target proteins are removed from the slide.
One of the detector antibodies against an alternate epitope on captured target-protein is conjugated with GO. Binding of another detector
antibody specific to phosphorylated sites (P) on target protein (a) or another non-overlapping epitope (b) conjugated with HRP completes the
formation of immuno-complex necessary for signal generation and subsequent tyramide mediated signal amplification through GO-HRP enzyme
channeling in the presence of glucose. The capture and detection antibodies were selected to minimize competition between them (i.e., all
antibodies can simultaneously bind their corresponding epitope on the signal transduction protein). (c) A slide configuration for CEER is shown.
Capture antibodies for each specific target protein are printed in triplicates in serial dilution. Each slide contains cell line controls for standard
curve generation for accurate quantitation of samples on each slide run. Internal quality control samples are run on each slide to ensure the
quality of data generated from each array-slide.
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phorylation upon EGF treatment (Figure 2b). Typically
only 2-10% of highly expressed RTKs are phosphorylated
upon ligand stimulation which equates to approximately 2
×1 0
4 to 1 × 10
5 phosphorylated receptors per MDA-MB-
468 or SKBr3 cell [18]. As shown in a cell titration experi-
ment in Figure 2a, CEER enabled us to detect approxi-
mately 10
4 phosphorylation events in both MDA-MB-468
and SKBr3 cells, thus demonstrating that this assay is cap-
able of producing single cell sensitivity. The RTK activa-
tion per cell upon growth factor treatment using CEER is
also summarized in Figure 2b.
To demonstrate the sensitivity of CEER compared
with a commonly used enzyme immunoassay, CEER and
ELISA were used in a side-by-side comparison to detect
phosphorylated HER1 (pHER1) and HER1 expression
(total HER1) in MDA-MB-468 and pHER2 and total
HER2 in SKBr3 serially diluted cell lysates. A signal sen-
sitivity comparison is illustrated by plotting cell numbers
o ft h et w oa s s a y sf o rp H E R 2 ,p H E R 1 ,H E R 2a n dH E R 1
in test samples (Figure 2c). The detection limit was
defined as the point at which the signal-to-noise ratio of
cell numbers was > 3. The plots show that the cell titra-
tion curves of ELISA were shifted right by more than 2
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Figure 2 CEER’s single cell sensitivity and capacity for functional profiling of pathway proteins. (a) The activation of HER1 and HER2 at a
sensitivity level of a single cell in MDA-MB468 and SKBr3 respectively are shown above. These cell lines express approximately 1 to 2 × 10
6
HER1 or HER2 RTKs on their cell membrane per cell. Microarray slide images for 3 cells, 1 cell, 0.3 cell and negative control are shown above the
cell titration curve. MDA-MB468 cells were treated with EGF to activate HER1 while HER2 is constitutively phosphorylated in SKBr3 cells. The cell
amount on each pad was generated by serial dilution. Capture antibodies were printed with 500 pl per spot in triplicates in serial dilutions of 1.0
mg/ml, 0.5 mg/ml, 0.25 mg/ml and 0.125 mg/ml. Relative signal intensity scale is shown for reference. (b) The western blot data were generated
from 12 μg of total protein per lane. The level of dominant RTK expression in each cell line was determined pre- and post- EGF or HRG
stimulation. The CEER determined per-cell RTK activation (RFU/cell) level for each cell line is summarized. Non-detectable signals in each cell lines
were indicated as ND in the table. (c) Detection of pHER1, pHER2, total HER1 and total HER2 in SKBR3 and MDA-MB-468 cells using CEER or
ELISA assays are shown. Sensitivity of CEER and ELISA assays were shown by detection limit, which was defined as cell numbers when signal
noise ratio (s/n) > 3. pHER1 in MDA-MB-468 cells (top left), pHER2 in SKBR3 cells (top right), HER1 in MDA-MB-468 cells (bottom left) and HER2 in
SKBR3 cells (bottom right). Closed square (red): HER2s or HER1s (RFU) detected by CEER assay; Closed circle (blue): HER2s or HER1s (OD450)
detected by ELISA assay.
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150-800 cells: pHER2 = 320 cells, HER2 = 150 cells,
pHER1 = 800 cells, and HER1 = 320 cells. In contrast,
the detection limit of the same analytes in the same
samples was determined to be 1 cell or less using CEER.
The EC50 value comparison for each analyte showed
greater than 3 log sensitivity enhancement by CEER
(Summary table in Figure 2c).
In order to quantitate the HER1 and HER2 expression
levels in the test samples to get an idea of the level of
sensitivity of CEER at the absolute receptor level, we
used purified recombinant HER1 and HER2 proteins (R
& D systems) as standards in an ELISA assay (data not
shown). The detection range for HER1 was 313-10000
pg and 156-10000 pg for HER2 in an ELISA. Based on
our assay results, we determined that there were
approximately 0.6 pg HER1 molecules per MDA-MB-
468 cell and 0.8 pg HER2 molecules per SKBr3 cell,
r e s p e c t i v e l y .T h u s ,o n eM D A - M B - 4 6 8c e l lc o n t a i n s~
2.0 × 10
6 HER1 receptors and one SKBr3 cell contains
~2 . 5×1 0
6 HER2 receptors, which is consistent with
other published results [18,20,21]. This analysis also
agrees with our previous calculations and reiterates that
CEER is able to detect 10
4-10
5 phosphorylated ErbB
receptors per cell in the breast cancer systems.
CEER can efficiently detect ErbB pathway activation in
breast cancer systems that lack HER2 gene amplification
Our studies thus far demonstrated the high sensitivity
and specificity of the CEER format. While pHER2 was
undetectable in MDA-MB-468 cells, they displayed 993
RFU/cell level of phosphorylated HER1 (pHER1) when
stimulated with EGF (Figure 2b). In contrast, EGF trea-
ted SKBr3 cells displayed substantially lower level of
pHER1 than pHER2 in CEER in agreement with their
known relative ErbB receptor expression levels. We next
wanted to interrogate the utility of CEER (both sensitiv-
ity and specificity) in breast cancer systems that lack
overexpressed HER2. This would be important as many
breast cancers do express HER2 but do not harbor over-
expressed or gene-amplified HER2 status (IHC; 3+ or
FISH; HER2/CEN17 > 2.2). We carried out the ErbB
pathway analysis using CEER in T47D cells. T47D cells
carry normal levels of HER2 (IHC based score of 0/1+)
that are substantially lower than SKBr3 cells [22]; how-
ever, a significant level of HER2 phosphorylation was
detected in this system when approximately 10 cells
were analyzed in a CEER format. Differential ErbB
receptor and pathway activation patterns were observed
when these cells were stimulated with either EGF/TGFa
or HRG ligands (Figure 2b and Figure 3). As T47D cells
express a significantly higher level of HER3 than HER1,
higher HER2 activation was observed when cells were
activated with HRG via HER2-HER3 heterodimer for-
mation. HRG treatment did not induce HER1 activation
in this cell population demonstrating assay specificity.
On the other hand, TGFa treatment of T47D cells
resulted in both HER1 and HER2 activation through
HER1-HER2 heterodimerization, although at a lower
level than HRG mediated activation. In addition to
HER1 and HER2, the differential phosphorylation pat-
terns of other RTKs that interact with ErbB-RTKs and
downstream pathway proteins were interrogated (Figure
3). Stronger activation of Shc was observed upon HRG
Figure 3 Detection of ligand specific activation of different signal transduction pathway proteins. T47D cells upon different ligand (TGFa,
HRGb or IGF1) treatment were analyzed for various RTK and subsequent downstream pathway protein activation.
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Page 5 of 15treatment, and PI3K was only activated with HRG treat-
ment, which is consistent with a HER3-mediated cellular
signal transduction process. Upon insulin-like growth
factor 1 (IGF1) treatment, T47D cells showed ligand-
specific IGF1-receptor (IGF1R) phosphorylation along
with some level of HER2 activation (Figure 3). Recent
evidence from trastuzumab-resistant breast cancer cell
lines suggests that functional heterodimerization of
HER2 and IGF1R may contribute to trastuzumab resis-
tance [23]. Binding of IGF1 to its receptor results in its
auto-phosphorylation and subsequent activation of
downstream proteins, especially the PI3K pathway, ulti-
mately resulting in increased cell proliferation. Overall,
these studies demonstrated the ErbB ligand-dependent
specificity of CEER in several breast cancer cell lines.
We next evaluated if CEER could be utilized in in vivo
samples to profile HER1 and HER2 in tumor tissues
obtained through (Fine Needle Aspirates) FNAs from
breast cancer xenografts (Table 1) with varying degrees
of ErbB-RTK expression [17-19,24]. BT474 is known to
have HER2 gene amplification and overexpresses the
HER2 protein. On the other hand, MDA-MB-435 and
MDA-MB-231 do not express gene amplified HER2 but
MDA-MB-231 expresses HER1 at high levels while both
H E R 1a n dH E R 2a r ee x p r e s s e da tm u c hl o w e rl e v e l si n
MDA-MB-435. We detected 4619 RFU/μg and 3813
RFU/μg of pHER1 and pHER2, respectively, in MD-MB-
231 xenograft tissue. A substantially higher level of
pHER2 (59890 RFU/μg) and moderate levels of pHER1
(6557 RFU/μg, due to co-expression with amplified
HER2) was detected in FNA samples obtained from a
BT474 xenograft. Very low HER1 and HER2 activation
(724 RFU/μg and 1301 RFU/μg, respectively) were
detected in FNAs obtained from MDA-MB-435 xeno-
graft (Table 1). Although MDA-MB-435 has been used
as a model for metastatic human breast cancer, interest-
ingly it has recently been revealed that this cell line
resembles melanoma according to gene expression pro-
filing; hence, our results were consistent with what has
been reported previously [25]. Taken together, our find-
ings from the xenograft-FNA model systems are concor-
dant with the parent cell line HER2 profiles. This
demonstrates that the CEER technology can be used to
detect activation of ErbB receptors in samples obtained
from both HER2 gene amplified and non-amplified
breast cancer systems including limited amounts of
tumor tissue isolated through minimally invasive FNA
procedures.
Comparison of CEER with IHC in primary human breast
tumors
Currently, IHC and FISH are widely used tests for HER2
detection in clinical breast cancer tissues. Although
there are some controversies concerning the measure-
ment of HER2 amplification in breast cancers, it is con-
ventionally accepted that trastuzumab is only effective
in a subset of breast cancers, those with elevated HER2
expression as assessed by these diagnostic assays. There
are specific guidelines recommended by the American
Society of Clinical Oncology (ASCO) and College of
American Pathologists (CAP) that define HER2 positive
and HER2-negative breast cancers based on IHC and
FISH assays [26]. To test the concordance of CEER and
IHC results, CEER-HER2 expression analysis was per-
formed on primary BCa tissues obtained from 227
patients with various IHC-HER2 statuses. All tissues
were procured with a minimum of 50% tumor content.
Although reporting expression/activation levels of
RTKs in RFUs is useful, results from CEER analysis
need to be normalized against standard controls before
they can be reliably utilized in clinical environments.
Hence, we developed algorithms for converting RFU
values into Computed Units (CU), a standard func-
tional unit based on cell line controls with known
HER1 and HER2 expression. For each slide, a standard
curve of serially diluted cell lysate was prepared from
MDA-MB-468 (HER1-positive) and SKBr3 (HER2-posi-
tive) cell lines as shown in Figure 1c. This made it
possible to obtain normalized levels of HER1 and/or
HER2 expression and the degree of phosphorylation in
each sample against standard cell lines. Hence, a sam-
ple with 1 CU of HER1 expression has a RFU value
equivalent to RFU value of 1 standard reference MDA-
MB-468 cell. As reference cells have 1~2 × 10
6 HER1
or HER2 receptors per cell with approximately 10%
phosphorylated receptors, 1 CU represents the expres-
sion of 1~2 × 10
6 RTKs or 1~2 × 10
5 phosphorylated
RTKs. The limit of detection (LOD) value by CU was
determined to be less than 1 CU for both pHER1 and
pHER2 in a CEER assay.
Table 1 CEER can be utilized to profile tumor cells present in FNAs
HER2 Gene Amplification HER1 (RTK/cell) HER2 (RTK/cell) pHER1 (RFU/μg) pHER2 (RFU/μg)
BT474 Yes 3 × 10
4 2.2 × 10
6 6557 59860
MDA-MB-435 No 1.3 × 10
4 2.2 × 10
3 724 1301
MDA-MB-231 No 1.3 × 10
5 6 ×10
4 4619 3813
The levels of HER1 and HER2 expression in cell lines used for xenograft models are shown as number of RTK expressed per cell (BT474, MDA-MB-435 and MDA-
MB-231 [12-15,22]). The degree of RTK activation in FNA samples obtained from xenograft models are shown in RFU per μg of tissue lysate.
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based on their HER2 status determined using IHC pro-
cedures based on ASCO/CAP guidelines. The HER2
expression levels (in 50 ng of total lysate protein) in
each IHC sub-group were subsequently determined by
CEER and are shown in Figure 4a. Most samples within
the HER2-IHC 3+ sub-group had significant level of
HER2 detected by CEER while a substantially lower
level of HER2 expression was detected in the other sub-
groups (2+, 1+ and 0); their quartile distribution is sum-
marized in Figure 4c. Based on this CEER HER2 break-
down, we observed 17% discordance between the HER2
status as determined by CEER and IHC as shown in Fig-
ure 4d, and this finding is similar to previously reported
findings [26-28]. A total of 100 samples (a subset of
227) from the various HER2-IHC sub-groups including
all samples with a discordant outcome between CEER
and IHC were further analyzed for their HER2 expres-
sion by immunoprecipitation western blot (IP-W). An
immunoprecipitation assay combined with a western
blot with HER2-specific antibodies is more accurate and
quantitative as compared to an IHC assay. In this subset
analysis, when compared to IP-W, IHC HER2 status
revealed 68% concordance to IP-W with 23.5% (8/34)
false negative calls (Figure 4e, left panels). When HER2
status between CEER and IP-W were compared, we
found a 91% concordance between them with no false
negative call by CEER (Figure 4e, right panels). As
patients with a false negative call would not receive
H E R 2 - t a r g e t e dt h e r a p y ,i ti sa b s o l u t e l yc r i t i c a lf o ra
technology to have minimal false negative calls to be
effective in providing clinical utility. When CEER-HER2
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Figure 4 Concordance of CEER with IHC in primary breast tumors. The distribution of HER2 expression based on CEER in each IHC sub-
group are shown in (a). The quantitative distribution within each sub-group is shown in (c). There were 17% (38/227) discordant calls between
IHC and CEER HER2 status (C - concordance, D - discordance). The outcome of IP-W analysis of 100 samples (including all with discordant calls)
are summarized in (e). The concordance between CEER and IP-W adjusted HER status are shown in (b) and (d). Representative IP-W images for
each sub-group are shown in (e).
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status (IPW/IHC), the concordance rate between CEER
and HER2-IHC improved from 83% to 96% (Figure 4d).
All discordant calls between IP-W and CEER were due
to the higher sensitivity of CEER; corrected IHC vs.
CEER HER2 status are shown in Figure 4b. These data
demonstrate the superiority of CEER in terms of its
high sensitivity and specificity in breast cancer clinical
samples with a significantly reduced false negative rate
frequently observed with HER2-IHC.
Expression of activated HER2 in circulating tumor cells
reveals an evolving and dynamic signaling pathway in
metastatic breast cancers
CTCs are gaining significant attention as they provide
an opportunity to perform non-invasive and tempo-
rally-relevant tumor assessments [13,14,16,29,30]. CTC
analysis from metastatic cancer patients provide an
additional opportunity to study how representative
they are of the metastatic cancers in terms of their
specific pathway activation as CTC presence has been
associated with worse progression-free and overall sur-
vival. However, in order to expand the utility of CTCs
as prognostic indicators of metastatic disease and
treatment response, the technology for interrogating
their pathway activation profiles must be highly sensi-
tive, specific, reproducible, standardized and related to
clinical outcomes.
In order to explore the capability of CEER to interro-
gate CTCs found in metastatic breast cancer patients,
whole blood samples (N = 113) were analyzed from 60
healthy controls (HCs) and 53 metastatic BCa patients
(from both 07ONC2 and 08ONC02 cohorts). Reference
values were determined based on data obtained from
HC subjects. The HER2 expression or activation distri-
butions in all samples are shown in Figure 5. The refer-
ence values were set from HC mean plus 2.3 × SD. The
differences between clinical samples and HCs were sta-
tistically significant (p < 0.01). The p-values were calcu-
lated using a two-sided Wilcoxon rank sum test. Based
on this analysis, we determined that the overall average
levels of phosphorylated HER2 in CTCs derived from
metastatic breast cancer patients was 4.25-fold higher
than those present in the healthy controls.
To determine pHER2 and total HER2 status in each
sample, the background was subtracted and the control
normalized signals were compared to the reference
values for each marker. The CU values for pHER2 and
total HER2 greater than the reference values are pre-
s e n t e di nT a b l e2 .O u to f2 7S t a g e3 / 4B C ap a t i e n t s
(07ONC2 cohort), 17 CTC-samples were collected from
metastatic BCa patients with a primary HER2-IHC nega-
tive status. 41% (7/17) patients with metastatic BCa and
with a primary HER2-negative status displayed detect-
able HER2 expression in their CTCs which is consistent
with published reports [31-39]. All of these CTCs from
Figure 5 CTC-HER2 profiling in BCa patients and HCs. The p-values were calculated using a two-sided Wilcoxon rank sum test, a
nonparametric test similar to a t-test. All of the comparisons show a statistically significant difference (p < 0.01). To determine pHER2 and tHER2
status, the background and reference values was subtracted (normalized CU). Scatter plots of normalized CU for pHER2, tHER2 and CK for BCa’s
and HC’s are shown.
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of HER2 activation (pHER2) as detected by CEER. Inter-
estingly, we also detected HER2 activation even without
apparent HER2 over-expression in 18% (3/17) of CTCs
from primary HER2-negative BCa patients. Within the
group of relapsed BCa patients with primary HER2-posi-
tive tumors, 60% of the collected CTC samples (6/10)
still showed HER2 expression. However, only 4 of the
HER2-positive CTC samples displayed an activated
HER2 status.
An additional interesting observation was revealed
from our CEER-based analysis of total and activated
HER2 in the CTCs of metastatic breast cancer patients.
While the levels of pHER2 in the CTCs collected from
primary IHC-HER2-positive (HER2 status determined
by IHC or FISH) patients who were still on trastuzumab
therapy were significant; overall they were lower in com-
parison to the pHER2 levels observed in the CTCs
derived from the primary IHC-HER2-negative patients.
As described earlier, CTCs obtained from primary IHC-
HER2-negative patients showed evidence of gaining a
HER2-positive status. Taken together, our data demon-
strate that discordance in HER2 status between the pri-
mary tumor and CTCs is not only at the level of HER2
expression but is also in terms of HER2 activation. One
patient in particular, (A02-028), with an extremely high
HER2 expression (19.4 CU) showed pHER2 level of
6.3CU. The pHER2/HER2 signal ratio in this patient is
0.32 (6.3/19.4), which is slightly higher than the typical
pHER2/HER2 ratio of BT474 type cells (0.25). Because
of the initial primary tumor HER2 status being negative,
patients such as these will most likely not receive any
HER2-targeted therapies.
In addition to detection of HER2 expression, we were
also able to detect cytokeratins (pan-CK) in CTC sam-
ples. The level of CK correlates with the amount of
CTCs in general, and the CKs in the CTCs of BCa
patients were significantly higher than the healthy con-
trols (Figure 5). However, CTCs stemming from differ-
ent subclasses of breast cancer may have different levels
of CK (100 MDA-MB-468 cells showed less than 9.7
CU whereas 10 SKBr3 cells showed 6.1 CU - data not
shown). In addition, the type of CK expressed also varies
in each tumor with different tissues of origin [40].
Therefore, CK values may not serve as an absolute
quantitative reference for the isolated CTCs. Further-
more, recent studies demonstrating the contribution of
EMT-derived mesenchymal cells to the CTC popula-
tions [41] may further hamper the utility of CKs in enu-
merating CTCs. Therefore, caution needs to be
exercised in relying solely on CKs as a reference marker
for enumerating CTCs; however, this issue will most
likely be resolved in the future with better CTC isolation
strategies. Nonetheless, CEER can be easily adapted to
interrogate markers that can be used to enumerate the
CTCs in addition to the active signaling pathways within
them.
Discussion
Development of companion diagnostics for targeted
therapeutics in oncology is an urgent need to streamline
efficient patient selection. Although interrogation of the
primary tumor in order to determine potential respon-
siveness to a targeted therapy is becoming frequent;
changes in the pattern of target expression, activation
and downstream signaling as the tumor progresses from
initial diagnosis to recurrence of metastatic disease are
virtually never assessed. This is important as tumors are
Table 2 Observation of HER2 conversion in circulating
tumor cells
Sample Primary IHC - HER2 pHER2 tHER2
A01-002 Positive 1.9 5.8
A01-003 1.7 5.8
A01-006 1.6 5.8
A01-014 1.7 7.3
A01-041 1.4 7.2
A02-027 0.1 ND
A02-034 3.9 5.9
A02-035 1.2 4.1
A02-036 0.1 1.7
A03-019 0.9 2.9
A02-039 Negative 1.1 ND
A02-052 2.1 7.0
A02-053 0.1 3.2
A02-056 0.5 ND
A03-008 0.7 ND
A01-019 1.8 5.9
A01-024 1.8 3.2
A01-028 3.1 4.0
A01-030 ND ND
A01-034 1.7 5.9
A01-042 0.3 2.5
A02-001 0.7 ND
A02-017 2.2 1.1
A02-021 2.1 6.9
A02-028 6.3 19.4
A02-029 3.9 6.0
A02-031 4.6 6.6
A total of 27 breast cancer samples analyzed for their HER2 expression and
activation are shown in the table. 17 blood samples were obtained from
metastatic breast cancer patients with primary HER2-IHC negative status. Up
to 59% (10/17) of initial HER2-IHC negative samples showed evidence of HER2
activation (pHER2) in their CTCs (Bold). CTCs with HER2 expression (tHER2)
were found in 7 (Bold) out of 17 (41%) blood samples obtained from
metastatic breast cancer patients with primary HER2 negative status. Levels of
HER2 expression and phosphorylation are shown in CU.
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cular circuitry being constantly modified with progres-
sion and treatment. To achieve this overarching goal,
there has been aggressive progress in several non-inva-
sive or minimally invasive tissue sampling methodolo-
gies in the past few years; however, meaningful
molecular characterization of these limited amounts of
clinical materials is challenging and is lagging behind.
We describe the development and application of a
highly sensitive, novel proteomic technology, CEER,
which can perform phosphorylation-driven analysis of
many proteins in small amounts of clinical samples in a
multiplexed manner. As demonstrated in this manu-
script, CEER can be performed on rare CTCs isolated
from blood or on limited number of tumor cells pro-
cured through FNAs. The multiplexed CEER technology
can facilitate longitudinal monitoring of tumor progres-
sion or therapeutic response outcomes. The ability to
quantitate the target protein activation state permits an
additional evaluation of the signal transduction proteins
beyond mere expression, potentially further predicting
the utility of various targeted therapies.
CEER utilizes the formation of a unique immuno-
complex requiring the co-localization of two detector
enzyme-conjugated-antibodieso n c es p e c i f i ca n t i b o d i e s
on the microarray surface have captured the target pro-
teins. The channeling events between two detector
enzymes with high turnover numbers (10
5/min for GO
and 10
4/min for HRP [42,43]) in proximity enable the
profiling of the RTK expression and activation in a
highly sensitive manner. Besides enhancing the
analytical specificity, the unique triplex assay configura-
tion of CEER overcomes the issues associated with
cross-reactivity found in a typical multiplexed immu-
noassay. This is particularly useful in the detection of
protein phosphorylations as phosphorylation-specific
antibodies are notorious for non-specifically binding to
closely related analytes [44-46]. Furthermore, the metho-
dology is flexible and assay components specific for
additional targets can be easily added into the multi-
plexed format with minimal disruption. Indeed, there
are other technologies in development for targeted pro-
teomic analysis of clinical samples such as Reverse
Phase Protein Arrays (RPPA) [47-49], Phospho-Flow
cytometry [50] and ELISA [51]. They each have their
specific advantages and shortcomings that are summar-
ized in Table 3. However, CEER is the first described
technique that incorporates the advantages of all of
these techniques while providing ultra high sensitivity
and specificity at a single cell level. Perhaps the only
limitation of CEER is the need for screening compatible
yet distinct triplex antibody sets for each target. How-
ever, with well-developed antibody production technolo-
gies, generating multiple antibodies specific for a target
protein is not an obstacle for CEER development. As
demonstrated in this manuscript, we have been success-
ful in the simultaneous detection of protein expression
and activation of EGFR, HER2, HER3, IGF1-R, c-MET,
c-KIT, PI3K, Shc and other downstream signal transduc-
tion proteins with extreme sensitivity and specificity.
Using the CEER technology, we focused on analyzing
the ErbB-RTK pathway activation profiles in both HER2
Table 3 Characteristics of CEER vs. Other Commonly Used Immunoassays
CEER Reverse Phase Protein Array PhosphoFlow ELISA
Sample Protein
Requirement
Native proteins Denatured proteins Fixed proteins Native or Fixed
proteins
Minimum Cell
Requirement
(Assay
Sensitivity)
1 cell 2500~15000 cells 1 × 10
4~1 × 10
6 cells 150 to 300 cells
Multiplex Format One sample, multiple analytes Multiple samples, one analyte One sample, multiple
analytes (limited)
Multiple samples,
one analyte
Assay Specificity ￿ High ￿ Low ￿ Low ￿ Medium
Advantages of
Assay
￿ Simultaneous analysis of multiple
analytes (e.g. selected analytes of a
signaling pathway) on a single sample.
￿ Suitable for clinical samples of rare cells
as well as limited solid tissue samples.
￿ Simultaneous analysis of multiple
samples for a single analyte.
￿ Suitable for samples of cells or solid
tissue.
￿ Detection of target
molecules within a cell
population in one sample.
￿ Suitable for blood
sample analysis.
￿ High
throughput.
Disadvantages of
Assay
￿ Screening compatible antibody sets for
each target.
￿ Need to print each sample; not
suitable for applications in clinical
samples from individual patients.
￿ Cross reaction of detector antibody.
￿ Not suitable for rare cell
analysis or solid tissue
samples.
￿ Requires a large number
of cells.
￿ Requires samples in
single cell suspension,
limiting its use.
￿ Low sensitivity
requires large
numbers of cells.
￿ Not suitable for
rare cell analysis.
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Page 10 of 15gene amplified and non-amplified breast cancer systems.
HER2 signaling pathway forms a crucial driver of tumor
growth in ~20-30% breast cancers. Breast cancer
patients, whether HER2-positive or HER2-negative,
develop recurrent metastatic disease with latency peri-
ods that can range from several years to even decades
[52]. CTCs play a crucial role in tumor dissemination,
and their monitoring during tumor dormancy periods
can allow physicians to follow cancer changes over time
as “real-time biopsies” [53,54]. CEER was used to suc-
cessfully analyze CTCs isolated from metastatic breast
cancer patients where the original primary tumors were
identified as either HER2-positive or HER2-negative
based on IHC analysis. Regardless of CTC isolation
methods used, enriched CTC samples typically contain
at least 10
4 or higher contaminating blood cells. As
CEER generates a signal only when binding partners for
specific corresponding epitopes are in proximity, it pro-
vides a realistic clinical means to investigate rare cells
present in a high non-target background cell population.
HER2 analysis in CTCs can have important clinical
significance for HER-targeted therapies. HER2-positive
CTCs are common in women with HER2-IHC-positive
primary breast tumors [36] and they were detected as
such using the CEER technology. Such patients may
benefit from secondary HER2-targeted therapy in an
adjuvant setting. More importantly, CEER established
the presence of HER2-positive CTCs in metastatic
breast cancer patients whose primary tumors were ori-
ginally deemed as HER2-negative based on IHC or FISH
analysis. This “HER2 conversion” event is consistent
with a growing body of evidence that HER2-positive sta-
tus can be acquired during disease recurrence or pro-
gression in breast cancer patients [31-39]. However,
CEER provided an additional and important readout in
that the HER2 expressed on CTCs was phosphorylated
indicating that the HER2 pathway was active in these
CTCs from metastatic breast cancer patients. Further-
more, the pHER2 expression levels in HER2-IHC-nega-
tive patients were higher than those detected in HER2-
IHC-positive patients some of who were receiving tras-
tuzumab therapy. It remains to be seen if the HER2
expression in HER2-positive CTCs would be responsive
to trastuzumab treatment. The ability to detect the
HER2 activation status in CTCs has important clinical
implications in terms of monitoring therapeutic
responses and for understanding the HER2 biology in
HER2-IHC-negative, metastatic breast cancer patients.
At this time we cannot rule out the possibility that
some of the HER2-IHC-negative primary breast cancers
may actually be false negatives due to the inherent inac-
curacy in IHC and FISH techniques and that a more
sensitive technology such as CEER would reveal these
cancers to have significant levels of HER2 expression.
This will be addressed in future studies when we have
access to the primary tumors and CTCs after metastasis
from the same patient.
CEER revealed an active HER2 pathway in CTCs from
HER2-IHC-negative breast cancer patients. Besides the
translational implications of this finding, it may provide
insight into the mechanism of breast cancer metastasis.
The underlying mechanism responsible for HER2 con-
version in these patients is unclear. It may be the result
of therapeutic or other selection pressures on the het-
erogeneous tumor cell population that lead to a shift in
the ErbB kinase signaling circuitry in the CTCs. Alterna-
tively, it could be due to selection of dormant cancer
cells that are HER2-positive. Although unproven, it may
also be provocative to suggest that conversion to an
active HER2 state in CTCs represents a transition to or
selection of a stem cell-like population. Recent evidence
demonstrates that overexpression of HER2 in breast
cancer cells increases the cancer stem cell population
[55]. Regardless of the mechanism behind HER2-conver-
sion, the presence of HER2 expression/activation in
CTCs requires further attention.
Detection of any CTCs before initiation of first-line
therapy in patients with metastatic breast cancer is pre-
dictive of a poorer progression-free and overall survival
[1,13]. Having a sensitive method such as CEER to
monitor the functional profile-pathway shift in CTCs
d u r i n gt h ec o u r s eo ft h e r a p ym a ys e r v ea sad i a g n o s t i c
marker for evaluating therapeutic outcomes and may
help in subsequent therapy selection decisions. This
would greatly enhance the value of CTC-based therapy
monitoring rather than a mere enumeration tool as it is
currently. As we can treat isolated CTCs using relevant
ligands, this technology can provide the “activation
potential” for CTCs in their route to a potential meta-
static site. As the relationship of HER2 gene status
between the primary breast cancer and synchronous dis-
tant metastasis has been reported to be concordant by
several groups and quite different by others [45,56-58],
it will be important to determine the correlation
between RTK status in CTCs versus primary and meta-
static lesions. These studies are currently ongoing in our
laboratories and will be reported in the future.
Conclusions
As having the capacity to predict potential therapy
responses based on functional pathway-profiling is cru-
cial in treating cancer patients, CEER provides an ideal
platform to analyze a comprehensive array of cancer-
causing biomarkers in various biological specimens and
samples even with a limited amount of materials avail-
able (such as CTCs). Due to the superior sensitivity and
specificity of this unique assay design, it may now be
possible to not only select patients before initiating
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keep up with the “evolving” disease. This would allow
for the determination of optimal therapy combinations
or sequencing to maximize therapy outcome.
Methods
Multiplexed microarray printing
Capture Abs were printed on nitrocellulose-coated glass
slides (FAST,
®, Whatman) using contact printers (QAr-
ray, Genetix). The spot diameter was approximately 175
μm and printed slides were kept in a desiccated cham-
ber at 4°C. Each spot included a tracking dye and speci-
fic capture Abs (mouse monoclonal against extra
cellular domains, ECDs). Approximately 500 pL of cap-
ture Abs were printed in triplicate and at serial dilution
concentrations of 1 mg/mL, 0.5 mg/mL, and 0.25 mg/
mL (Figure 1c). Purified mouse-IgGs were printed as a
negative control. Analytical calibration reactions were
performed on 8 pads and internal quality control reac-
tions on 2 pads. Each slide allows processing of up to 4
unknown patient samples.
Antibody conjugation and purification
Target specific-Abs (mouse monoclonal against intracel-
lular domains, ICDs or p-Tyr) and corresponding detec-
tor enzymes were activated with a bi-functional cross-
linker, succinimidyl-4-(N-maleimidomethyl) cyclohex-
ane-1-carboxylate (SMCC) to make detector Ab-conju-
gates. The conjugates were purified by HPLC using a
size-exclusion column. The Ab activities in the purified
conjugates were detected by competition ELISA and
enzyme activity was detected by a functional assay speci-
fic for each detector enzyme.
Collaborative Enzyme Enhanced Reactive-immunoassay
(CEER)
Slides were rinsed 2 times with TBST (50 mM Tris/150
mM NaCl/0.1% Tween-20, pH 7.2-7.4), blocked with 80
μL of Whatman Blocking Buffer for 1 hr at room tem-
perature (RT), and then washed 2 times with TBST.
Serially diluted cell lysate controls in 80 μLo fd i l u t i o n
buffer (2% BSA/0.1% Triton X-100/TBS, pH 7.2-7.4)
and samples were added to sub-arrays designated for
standards on the slide and incubated for 1 hour (hr) at
RT (Figure 1c). After incubation, slides were washed 4
times, 3 minutes (min) each time. The detector Abs
were added in 80 μL of the reaction buffer and incu-
bated for 2 hrs at RT. Unbound secondary detector Abs
were removed by washing with TBST. The activation
state-independent Abs were conjugated with the chan-
neling enzyme, GO, and with the signal amplification
moiety, HRP. When GO is supplied with a substrate
such as glucose, it generates hydrogen peroxide (H2O2).
When HRP is in close proximity to GO, H2O2 is
channeled to HRP where it forms a stable complex. The
HRP-H2O2 complex generates an amplified signal using
a fluorogenic substrate such as tyramide to generate a
reactive tyramide radical that covalently binds nearby
nucleophilic residues. 80 μL of biotin-tyramide (400 μg/
mL in ethanol, Perkin Elmer Life Science) at 5 μg/ml in
50 mM glucose/PBS was added to each pad and incu-
bated for 15 min in the dark, then washed with TBST 4
times for 3 min each. The local deposition of activated
biotin-tyramide was detected upon the addition of strep-
tavidin (SA)-labeled Alexa647 (in PBS, Invitrogen) at 0.5
μg/ml (1:4000 dilution) in 2% BSA/0.1% Triton/TBS for
40 min. Upon completion of incubation, slides were
washed 4 times with TBST, dried and kept in the dark
until scanning on the microarray scanner.
Cell line samples
SKBr3, MDA-MB-468, T47D and BT474 cell lines with
varying degrees of ErbB-RTK expression [17-19] were
obtained from ATCC and grown at 37°C in 5% CO2 for
SKBr3 (McCoy’s 5A medium with 10% FBS), MDA-MB-
468 (Dulbecco’s minimal essential medium, DMEM,
10% FBS), BT474 (DMEM, 10% FBS), and T47D (RPMI
1640, 10% FBS, 0.2 U/ml bovine insulin). Cells were har-
vested, counted and washed with 1× PBS, then stimu-
lated with 100 nM epidermal growth factor (EGF) or
transforming growth factor a (TGFa), 20 nM heregulin
b (HRGb) or both in serum-free growth media for 5
min. When Insulin-like Growth factor-1 (IGF1) was
used, cells were treated with 100 ng/mL of IGF1 for 15
min. Stimulated cells were washed with 1× PBS and
then lysed (lysis buffer: 50 mM Tris, pH 7.4, 150 mM
N a C l ,1 %T r i t i o nX - 1 0 0a n d2m MN a 3VO4)a n dk e p t
on ice for 30 min before taking the supernatant for a
subsequent assay or kept at -80°C.
Clinical blood samples
Blood samples from cancer patients (N = 53) and
healthy controls (HCs) (N = 60) were collected accord-
ing to the IRB approved protocol and informed consent
obtained. Prior history of cancer or other serious
chronic diseases were excluded from HCs. Specimens
were shipped within 24 hrs and processed the same day,
with resulting lysates stored at -80°C. All samples were
taken from adult subjects (> 18 to < 88 years [yrs]) and
sourced from multiple CRO sites. Diagnosis was per-
formed according to RECIST (Response Evaluation Cri-
teria in Solid Tumors). Whole blood from patients with
histologically confirmed solid carcinoma with regional
lymph node or distant metastases (Stage 3b or 4 -
cohort 07ONC02, N = 27) were collected. Subjects with
Stage 3b breast carcinoma had region lymph node sta-
ging of N1, N2, or N3. Samples were collected regard-
less of their therapy status. Whole blood samples from
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breast cancer, and who were about to start systemic
therapy (cohort 08ONC02, N = 26) were collected at
base line. Both cohorts had similar age distributions
with a baseline mean age of 57 ± 13 yrs. Extent of dis-
ease in both cohorts was determined by physical exami-
nation and imaging studies as per the primary physician.
The tests utilized included one or more of the following:
bone scans, PET/CT scans, CT of the abdomen, chest
radiograph and/or CT of the chest for visceral metas-
tases, sonogram and/or MRI for soft tissue disease. For
CTC evaluation, 7.5 ml of blood samples were drawn
into 10-ml evacuated ethylenediamine tetraacetic acid
(EDTA) tubes. The CellSearch System (Veridex) was
used for immuno-magnetic CTC isolation according to
the protocol previously described using ferrofluids con-
jugated to Ab against epithelial cell adhesion molecule
[59]. Enriched CTCs from blood were stimulated as
described above.
Tissue sample collection
Flash frozen breast cancer tissues were obtained from
patients with ductal carcinoma at stage II or III (ILS
Bio). HER2-IHC status was available for all samples.
Xenograft models were generated using human breast
cancer cell lines by subcutaneous injection into nude
mice. When tumor size reached 400 mm
3, tissue sam-
ples were collected by passing a 23 gauge needle
attached to an evacuated syringe through each tumor 5
times. Collected samples from frozen tissues and xeno-
grafts were lysed in 100 μl of lysis buffer. Lysed samples
were kept on ice for 30 min and centrifuged. Protein
concentrations of supernatants were determined by BCA
protein assay kit (Pierce), and the resulting lysates were
stored at -80°C before subsequent analysis.
Western blotting
Cell lysates for each cell line were aliquoted into single
use vials. The protein concentration was determined by
BCA protein assay kit (Pierce). Samples were prepared
with sample buffer containing b-mercaptoethanol, boiled
for 5 min, cooled to RT and loaded onto a NuPage
(Invitrogen) 4 - 12% gel. Upon completion, the sepa-
rated proteins were transferred to a nitrocellulose mem-
brane, then washed, blocked with 5% milk blotto, and
incubated with the 1° then 2° Abs before the detection
process using 5-Bromo-4-Chloro-3’-Indolyphosphate p-
Toluidine Salt (BCIP) and Nitro-Blue Tetrazolium
Chloride (NBT). For the immunoprecipitation-western
(IP-W) process for HER2 in tissues, sample lysates were
incubated with magnetic beads conjugated with antibo-
dies against ICD of HER2 overnight on a rocker at 4°C.
The immuno-magnetically enriched lysates were then
processed as described above.
Data analysis
Each slide was scanned at three photomultiplier (PMT)
gain settings to increase the effective dynamic range.
Background corrected signal intensities were averaged
for replicate spots printed in triplicate. The relative
fluorescence value of the respective reagent blank was
subtracted from each sample. Several quality criteria
were used to filter data from further analysis including
limits on the spot footprint, coefficient of variation for
spot replicates, overall pad background and the intensity
of the reagent blank.
For each assay, a sigmoidal standard curve was gener-
ated from seven concentrations of serially diluted cell
lysates prepared from cell lines MDA-MB-468 (HER1-
positive) and SKBr3 (HER2-positive). Each curve was
plotted as a function of signal intensity vs. log concentra-
tion derived units, CU (Computed Unit). The data were fit
to a five parameter equation by nonlinear regression [60],
simultaneously fitting all three dilutions of the capture Ab.
Fitting was carried out using R, an open source statistical
software package [61]. The individual predictions from
each of the standard curves (3 capture Ab dilutions and 3
PMT gain-set scanning) were combined into a single, final
prediction. The final prediction was calculated by a
weighted (determined by the slope) average of the indivi-
dual predictions and then designated as CU.
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